Origin
Origin is a YC Winter 2026 (W26) company. Based in San Francisco, CA, USA. Team of 4.
About Origin
Summary
Origin builds patient-derived cancer single-cell datasets that map how individual cancer cells respond to drugs and genetic medicines under defined DNA switches. Pharmaceutical and AI companies license these datasets to predict which patient populations will respond to a given therapy before a trial is designed, replacing the costly process of learning that only after a trial reads out. The goal is to raise oncology trial success rates by identifying responder profiles at population scale ahead of enrollment.
Business model
Licensing fees paid by pharmaceutical and AI companies for access to the dataset.
Go-to-market
Pharma and AI drug-development companies are the buyers; access is initiated through a direct request form on the Origin website.
From the Y Combinator listing
AI and Data for Cancer Therapeutics
Creating the largest patient-derived cancer single-cell dataset for licensing to pharmaceutical and AI companies. These datasets are unique as they screen the effects of various drugs and genetic medicines under the control of our DNA switches.
Facts
- Healthcare / Healthcare -> Drug Discovery and Delivery
- San Francisco, CA, USA
- 4
- Active
- Early
Founders (2)
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works